Recent News for IDXG - Interpace Diagnostics Group, Inc.

Date Title
May 14 Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript
May 14 Edited Transcript of IDXG earnings conference call or presentation 13-May-19 8:30pm GMT
May 13 Interpace Diagnostics misses by $0.04, misses on revenue
May 13 Interpace Q1 revenue up 25%
May 13 Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
May 9 Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
May 6 Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
May 1 Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
Apr 29 Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) Shift From Loss To Profit
Apr 25 Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
Apr 23 Interpace Diagnostics Announces New York State Approval
Apr 2 Interpace up 1% on new test coverage
Apr 2 Interpace Diagnostics Announces New Coverage of Thyroid Testing by Medica
Mar 21 Interpace Diagnostics Group Inc (IDXG) Files 10-K for the Fiscal Year Ended on December 31, 2018
Mar 20 Edited Transcript of IDXG earnings conference call or presentation 19-Mar-19 8:30pm GMT
Mar 20 Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q4 2018 Results - Earnings Call Transcript
Mar 19 Interpace Diagnostics revenue in-line
Mar 19 Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
Mar 19 Earnings Scheduled For March 19, 2019
Mar 7 What Kind Of Shareholder Owns Most Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Stock?
Mar 4 Interpace Diagnostics Receives Regional Award as 2018 Top Life Sciences Company
Feb 28 Interpace Diagnostics Announces Preliminary 2018 Revenues
Feb 19 Interpace Diagnostics Announces First Independent Publication Demonstrating Clinical Utility of BarreGEN®
Feb 4 Interpace Diagnostics to Attend BIO CEO & Investor Conference in New York City
Jan 29  Interpace Diagnostics Announces Closing of $7.0 Million Public Offering of Common Stock

Back to the Main IDXG Page...